Thomas M Simon

US Patent:

6593361, Jul 15, 2003

Filed:

Oct 12, 2001

Appl. No.:

09/976127

Inventors:

Stacia Kargman - Pointe Claire Dorval, Quebec H9R 4P8, CA
Jilly Evans - Pointe Claire Dorval, Quebec H9R 4P8, CA
Thomas J. Simon - Blue Bell PA 19422

International Classification:

A61K 3134

US Classification:

514461, 514241, 514242, 514252, 514267, 514359, 514363, 514365, 514372, 514374, 514378, 514383, 514451, 514444, 514473, 514499

Abstract:

This invention is directed to a method of retarding or preventing the transformation of a colonic adenoma to a colonic adenocarcinoma comprising the administration to a patient with FAP or a patient with one or more of said adenomas a non-toxic therapeutically effective amount of NSAID, said amount effective to inhibit the PGHS-2 in said adenoma. The preferred method comprises the administration of a specific PGHS-2 inhibiting agent as defined herein.

US Patent:

6649649, Nov 18, 2003

Filed:

Mar 2, 1999

Appl. No.:

09/261034

Inventors:

Stacia Kargman - Hampstead, CA
Thomas J. Simon - Berwyn PA
Jilly Evans - Brossard, CA

Assignee:

Merck Co., Inc. - Rahway NJ
Merck Frosst Canada, Co. - Kirkland

International Classification:

A61K 3134

US Classification:

514461, 514241, 514242, 514252, 514267, 514359, 514363, 514365, 514372, 514374, 514378, 514383, 514451, 514444, 514473, 514499

Abstract:

This invention is directed to a method of retarding or preventing the transformation of a colonic adenoma to a colonic adenocarcinoma comprising the administration to a patient with FAP or a patient with one or more of said adenomas a non-toxic therapeutically effective amount of NSAID, said amount effective to inhibit the PGHS-2 in said adenoma. The preferred method comprises the administration of a specific PGHS-2 inhibiting agent as defined herein.

US Patent:

20050215611, Sep 29, 2005

Filed:

May 9, 2003

Appl. No.:

10/513085

Inventors:

Richard Hunt - Burlington, CA
Thomas Simon - Bryn Mawr PA, US

International Classification:

A61K031/415

US Classification:

514406000

Abstract:

The present invention encompasses a method for treating a chronic cyclooxygenase-2 mediated disease or condition and reducing the risk of a thrombotic cardiovascular event in a human patient in need of such treatment and at risk of a thrombotic cardiovascular event comprising orally concomitantly or sequentially administering to said patient a cyclooxygenase-2 selective inhibitor in an amount effective to treat the cyclooxygenase-2 mediated disease or condition and nitric oxide releasing aspirin in an amount effective to reduce the risk of the thrombotic cardiovascular event while maintaining a high level of upper gastrointestinal safety and tolerability. The invention also encompasses a method for treating a chronic cyclooxygenase-2 mediated disease or condition and reducing the risk of a thrombotic cardiovascular event in a human patient in need of such treatment and at risk of a thrombotic cardiovascular event comprising orally concomitantly or sequentially administering to said patient a nitric oxide releasing-cyclooxygenase-2 selective inhibitor in an amount effective to treat the cyclooxygenase-2 mediated disease or condition and aspirin in an amount effective to reduce the risk of the thrombotic cardiovascular event while maintaining a high level of upper gastrointestinal safety and tolerability. Pharmaceutical compositions are also encompassed.

US Patent:

20080096927, Apr 24, 2008

Filed:

Aug 19, 2005

Appl. No.:

11/660195

Inventors:

Thomas Simon - Bryn Mawr PA, US
Alise Reicin - Englewood NJ, US
Richard Hunt - Ontario, CA

International Classification:

A61K 31/4439
A61K 31/365
A61K 31/444
A61P 19/00
A61P 9/00

US Classification:

514334000, 514338000, 514473000

Abstract:

The invention encompasses a pharmaceutical composition comprising a therapeutically effective amount of a cyclooxygenase-2 selective inhibitor selected from rofecoxib and etoricoxib or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of a proton pump inhibitor selected from the group consisting of: omeprazole, lansoprazole, rabeprazole, pantoprazole, and esomeprazole, or a pharmaceutically acceptable salt of any of the aforementioned, in combination with a pharmaceutically acceptable carrier. The invention also encompasses a method for treating a cyclooxygenase-2 mediated disease or condition in a human patient at risk of a thrombotic cardiovascular event, wherein the patient is on aspirin therapy to reduce the risk of the thrombotic cardiovascular event, comprising administering to the patient this pharmaceutical composition.

US Patent:

59689749, Oct 19, 1999

Filed:

Oct 10, 1997

Appl. No.:

8/948873

Inventors:

Stacia Kargman - Hampstead, CA
Jilly Evans - Brossard, CA
Thomas J. Simon - Berwyn PA

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 3134

US Classification:

514461

Abstract:

This invention is directed to a method of retarding or preventing the transformation of a colonic adenoma to a colonic adenocarcinoma comprising the administration to a patient with FAP or a patient with one or more of said adenomas a non-toxic therapeutically effective amount of NSAID, said amount effective to inhibit the PGHS-2 in said adenoma. The preferred method comprises the administration of a specific PGHS-2 inhibiting agent as defined herein.

US Patent:

58542671, Dec 29, 1998

Filed:

Jun 2, 1995

Appl. No.:

8/459182

Inventors:

Roger Berlin - Haverford PA
Thomas N. Gates - Bonita Springs FL
Thomas Simon - Berwyn PA

Assignee:

Merck & Co., Inc. - Rahway NJ
Mc Neil-PPC, Inc. - Skillman NJ

International Classification:

A61K 31425

US Classification:

514370

Abstract:

A method for preventing heartburn episodes in a patient susceptible to suffering heartburn episodes following ingestion of heartburn-inducing food or beverage, comprising administering to the patient, 30 minutes prior to consumption by the patient of the food or beverage, a composition comprising an amount of famotidine of 10 mg.

US Patent:

56677944, Sep 16, 1997

Filed:

Sep 11, 1996

Appl. No.:

8/710078

Inventors:

Thomas Simon - Berwyn PA
Roger Berlin - Haverford PA

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 3300

US Classification:

424401

Abstract:

A method for treating a patient suffering from heartburn and having no substantial esophageal erosion, comprising administering to the patient a composition comprising an amount of famotidine between about 5 mg and 10 mg. In one embodiment, the amount of famotidine is about 5 mg. In another embodiment, the amount of famotidine is about 10 mg. A method for treating a patient suffering from heartburn and having no substantial esophageal erosion, comprising administering to the patient a composition comprising an amount of famotidine between about 5 mg and 10 mg, and an antacid. In one embodiment, the amount of famotidine is about 5 mg. In another embodiment, the amount of famotidine is about 10 mg.